PGPE Buyback Expands as Private Equity Trust Starts Wind-Down

A small trade at a turning point

Partners Group Private Equity Limited (PGPE) put out a routine buyback notice this week, but it came at an unusual moment. On 7 October 2026, the London-listed trust bought back 15,899 of its ordinary shares at a weighted average price of about €6.9913. It will hold them in treasury, which takes the treasury total to 3,288,731 shares and leaves 65,862,437 voting shares13. The purchase cost roughly €111,000, which is tiny for a company with a market value in the mid-hundreds of millions.

The date is what matters. The same day, shareholders approved a managed wind-down, so the trust will now sell its whole portfolio21. Treasury buybacks will happen alongside that process from here on. They are no longer a way to manage the discount on a fund that keeps running. They are one of the ways shareholders get cash back while the portfolio is sold off, and they shape how that cash is shared between investors who sell now and investors who wait.

How the buyback programme has been running

The recent filings show steady, low-volume buying. On 7 September the company bought 12,201 shares at about €7.22, which left 2,897,960 shares in treasury12. A larger purchase of 30,000 shares on 21 September, at about €6.99, raised the treasury count to 3,147,70614. When voting closed on 5 October, the company held 3,272,832 treasury shares21. That is roughly 390,000 shares bought back in a month, while the price drifted from the low €7s to just under €7.

The bigger news came in a separate statement. PGPE said its capital allocation policy, adopted in March 2024, left no free cash flow for buybacks as of 30 September19. Under that rulebook, the board would not normally have added any money to the programme. It added €10 million anyway, on a discretionary basis. That sits on top of about €4.8 million left over from allocations made in October 2025 and April 2026, and the board wants to spend the combined amount by 31 January 20271916. The board said the extra money was meant to provide liquidity during the switch to selling the portfolio. It also said the old capital allocation policy stopped applying once the wind-down started20.

At prices close to €7, about €14.8 million would buy back somewhere around 2 million shares, or about 3% of the voting shares. That is a rough estimate. It means the buyback will soak up some selling pressure, but it cannot change the share price on its own.

Why shareholders chose to exit

The wind-down happened because shareholders pushed for it. In June, the board proposed splitting the company into two share classes. Investors would choose between continuing shares that kept the long-term strategy and realisation shares that would gradually return cash75. When the plan was first described, realisation shares were to be capped at 30% of issued capital5. The board later raised that limit to 40% after talking to large institutions28.

Demand blew past it. Holders of 48,829,366 shares, or 74.12% of the eligible total, asked to switch to realisation shares25. That killed the two-class plan, and the board instead put a single resolution to wind down the whole portfolio23. It passed on 7 October with 99.89% of votes cast in favour. Turnout was about 62% of the voting rights2126. Chair Peter McKellar said the board would oversee an orderly sale and would start returning proceeds twice a year from 31 March 202721. As part of the change, the dividend reinvestment plan ends, and the sterling trading line (PEYS) will close on 8 October 202726.

The reports differ on a few details. One German-language outlet said the 74.1% vote happened "roughly a week" before 8 October and credited Reuters18. The company's own election results are dated 5 October25. Estimates of the company's size also vary a little: £457 million in UK trade coverage2224, €461 million on one data service15, and close to €470 million on another19. None of these differences changes what happened.

The discount and the results behind it

The core problem is that the shares trade far below the stated value of the portfolio. Net asset value (NAV) per share fell from €13.00 at the end of 2025 to €11.57 at 30 June. Over the same period, the discount between the share price and NAV widened from 20% to 39%1. The trust called its first-half performance "poor". It said the discount was made worse by speculation about two large holdings and by some institutional investors leaving after the June proposal1. In its buyback statement, the board said the wait for a vote on the restructuring, combined with weak performance, had added to selling pressure19.

Most of the damage came from a handful of investments. Four assets (USIC, Emeria, Pharmathen and Ammega) caused about 6.4 percentage points of an 8.3% drop in gross portfolio value. Without them, the rest of the portfolio fell just 1.9%2. Pharmathen was written down to zero after a US FDA import alert. The company said the business's likely value was not enough to cover its existing debt10.

Debt in the portfolio

That Pharmathen detail shows the role private credit plays in these deals. Most private equity buyouts are financed largely with borrowed money. When a company's earnings fall, the lenders get paid first and the equity can be wiped out. PGPE's 20 largest holdings carried net debt of 6.9 times EBITDA (a measure of operating earnings) at mid-year. Earnings at those companies grew just 4.5% over 12 months, well below the trust's historical range of 13–15%2. Debt that high leaves little room for error when growth slows, and that matters more now that the trust is a seller with a public timetable.

The trust's own balance sheet is in better shape. It reported about €29 million in cash and a €150 million credit facility it has not drawn at all1522. That should mean it is not forced to sell assets to raise money, which is probably the biggest reassurance for shareholders right now.

Can it sell at book value?

The trust has shown it can sell assets in difficult markets. In the first half it received about €111 million from sales and other distributions, equal to roughly 14% of net assets2. One of the larger exits was Clario, the clinical-trial data company, which was sold to Thermo Fisher Scientific at an enterprise value of $9.4 billion10. Management has named Galderma, Rosen, Vishal Mega Mart and Telepass as candidates for future exits2.

The pace has slowed recently. In the third quarter, the trust received €4.8 million from the portfolio but invested €9.2 million16. A wind-down should reverse that balance. One analysis noted that only about a third of the first-half proceeds reached shareholders, because the rest went on new deals, reserves and support for portfolio companies28. That analysis also found that during the wind-down, the base management fee falls from 1.5% to 1.25%, while the performance fee arrangement stays as it is28.

What this says about Partners Group

The trust has its own board and its own shareholders, but the outcome reflects pressure across its manager. Partners Group capped withdrawals from its Global Value SICAV, its main open-ended (evergreen) fund, at 5% of NAV per quarter after investors asked to withdraw an estimated 9.8%5. It plans to split that fund into one part focused on growth and another that pays out cash from asset sales18. Jefferies cut its price target on Partners Group to CHF 605 from CHF 710, pointing to the drag from the evergreen funds18. One report says Partners Group has been moving older assets into vehicles built to sell them and return cash29.

The pattern is consistent. Investors in Partners Group's funds increasingly want their money back, and its listed trust and evergreen funds are both under pressure.

Outlook

This does not look like a distressed sale. The trust has cash, an untouched credit line and a record of recent exits. Even so, a buyer paying about €7 for a share last valued above €11.50 is betting that assets can be sold at prices close to their book values, and quickly enough to beat fees and the cost of waiting28. The €14.8 million buyback gives some liquidity to shareholders who sell now. Its effect on those who stay depends on whether the shares are bought back well below what the portfolio eventually fetches.

The key test comes in March 2027, when the first distribution is due. By then, investors should be able to see how sale prices compare with the values the trust has been reporting.